Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. — Clinical Trial Site

185 Registered trials

85 Currently recruiting

Organisation

Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

Location

Porto, Portugal

Identifier

ORG-100033662

Address

Rua Dr. Antonio Bernardino De Almeida, 4200-072, Portugal

Departments

-
#2000:Serviço Oncologia Médica
#2142: Serviço de Hematologia
#3002: Serviço de Oncologia Médica
#4000: Serviço de Oncologia Médica
#9000:Serviço de Oncologia Médica
1500 : Oncologia Médica
2101: Serviço de Oncologia Médica
2900: Serviço de Hematologia
3401:Serviço de Oncologia Médica
351007: Oncologia
35106: Oncologia
35108: Oncologia Medica
4401: Serviço de Oncologia Médica
5801:Anesthesiology/Reanimation
5805:Oncologia Medica
705: Oncologia Medica
93149007: Oncologia Medica
Bone Marrow Transplantation Service
Centro de Investigação
Clinical Hematology
Day Hospital
Departamento de Oncologia
Department of Hematology and Bone Marrow Transplant
Department: Medical Oncology
Hematologia
Hematologia Clínica
Hematologia e Transplantação de Medula
Hematology
Hematology and Bone Marrow Transplant Department
Hematology and bone marrow transplantation service
Hematology Department
INSTITUITO PORTUGUES DE ONCOLOGIA DO PORTO CLIN. ONCOL. IV( #22)
Medical Management
Medical Oncology
Medical oncology - Breast
Medical oncology - Ovarian
Medical Oncology Departament
Medical Oncology Department
Medical Oncology Service
N/A
NA
Not Applicable
Onco-Hematologia
Oncohematology
Oncologia
Oncologia Médica
Oncology
Oncology Department
Pediatric
Pediatric Service
Pediatrics
Reumatology
Service of Medical Oncology
Serviço de Gastrenterologia
Serviço de Hematologia e Transplantação de Medula Óssea
Serviço de Hematologia e Transplantação de Medula Ósses
Servico de Medicina Oncologica
Serviço de Onco-Hematologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria
Serviço de Urologia
Unidade de Investigação Clínica
Urology

Clinical trials at this site (185)

Search interface

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting

2023-510384-36-00 Newly Diagnosed Multiple Myeloma 5 2022-09-13
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic… Recruiting

2024-516010-38-00 Participants with Locally Advanced or Metastatic HER2-E 1 2022-04-25
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) foll… Recruiting

2024-518804-32-00 Non-Small Cell Lung Cancer (NSCLC) 9 2021-02-16
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Rhabdoyosarcoma 9 2020-10-07
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Acute Lymphoblastic Leukaemia 10 2020-07-13
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase I/II trial of MK-3475 (pembrolizumab) in children's solid tumors and lymphoma Recruiting

2022-501257-36-00 Treatment of advanced melanoma, or advanced, relapsed o 9 2015-03-19
An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr… Recruiting

2023-503479-79-00 Metastatic Cancer 4 2011-06-17
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended

2023-505394-32-00 chronic graft versus host disease 5 2025-02-06
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Breast Cancer 9 2024-10-02
An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended

2023-508219-21-00 BTC - Biliary Tract Cancer 5 2024-09-12
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28